A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Summary

This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

Timeline

Start

2017-03-15

Primary completion

2018-10-02

Completion

2018-10-02

Outcome

Outcome not reported

Stopped: “As the feeder study (AZES) was stopped for futility after an independent assessment, this trial was also stopped.”

Drugs

Indications